Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

Migraine Drugs Market is Expected To Demonstrate a CAGR of 3.5% by 2025

Author: Pragya Tripathi
by Pragya Tripathi
Posted: Nov 29, 2018

Global Migraine Drugs Market: Snapshot

The global migraine drugs market has considerable room for growth in the absence of a permanent cure for the condition and growing genericization of drugs. Hence, established companies in the market are seen upping allocations on research and development to come up with better drugs to satisfy the unmet demands, and thereby grow their sales and revenues. In the upcoming years, the market is expected to see entry of aspiring players too. All these will help to increase competition.

Migraine is a common occurrence worldwide. Hence, with the increasing global population, particularly female population – who are more prone to have migraine, the market for the drugs will likely rise at a steady pace. Posing a challenge to the market, on the downside, is the easy availability of generics and over reliance on over the counter (OTC) pain killers and other drugs in emerging and under developed markets.

Browse Press Release @

https://www.transparencymarketresearch.com/pressrelease/migraine-drugs-market.htm

As per a report by Transparency Market Research, the global migraine drugs market will likely expand at a lackluster CAGR of 3.5% during the period between 2017 and 2025 to become worth US$3.72 bn by 2025 from US$2.72 bn in 2016.

Triptans Make Abortive Treatment Segment Dominant

Depending upon the available treatments, the global market for migraine drugs can be divided into abortive treatment and prophylactic treatment. The abortive treatment can be further segmented into triptans, ergot alkoids, etc. The prophylactic treatment segment can be further divided into botulinum toxin, topiramate, etc. At present, the segment of abortive treatment leads the market with a higher share. The triptans are primarily powering the growth of the segment. The segment of prophylactic treatment is also expected to see steady growth in the next couple of years on the back of topiramate, which will likely rise at 3.4% CAGR in the forecast period. Increasing incidences of chronic migraine and rise in inclination towards prophylactic treatment of migraine is projected to fuel this growth.

Request for Sample Copy of Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=31136

Depending upon the route of administration, global migraine drugs market can again be classified into injectable, oral, and others including nasal sprays, transdermal patches, etc. Of them, oral route of administration accounts for a dominant share in the market because of their relatively cheaper price and easy availability of orally administrable drugs, namely triptans and topiramate.

Greater Healthcare Expenditure Propels North America Market to Fore

Geographically, North America currently runs the show in the global migraine drugs market. In future too, it is predicted to retain its leading share by rising at a CAGR of 3.4% from 2017 to 2025 to clock a revenue of US$2.13 bn by 2025-end. Factors pushing the market in the region to the fore are greater healthcare expenditure, rising occurrence of migraine, and availability of specialty migraine drugs. Europe trails North America in terms of market share and is forecasted to pull in a revenue to the tune of US$741.4 mn by 2025 by rising at a CAGR of 3.4% from 2017 to 2025.

Request Report Brochure @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=31136

Vis-à-vis growth rate, Asia Pacific is projected to surpass all other regions by registering a CAGR of 3.8% in the forecast period on the back of growing healthcare expenditure and shift of focus by key players in emerging markets in India and China.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research

State Tower,

90 State Street, Suite 700

Albany, NY 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

About the Author

My name is Pragya Tripathi and I work with the Digital Marketing and Editorial team of Transparency Market Research, a market intelligence firms based in India & Usa.

Rate this Article
Leave a Comment
Author Thumbnail
I Agree:
Comment 
Pictures
Author: Pragya Tripathi

Pragya Tripathi

Member since: Sep 17, 2018
Published articles: 1086

Related Articles